Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus retrospective cohort study

Hypertension

Volumn 63, Issue 5, 2014, Pages 977-983

  Padwal, Raj ^a,b,c   Lin, Mu ^a   Etminan, Mahyar ^b,c   Eurich, Dean T ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Angiotensin receptor antagonists; Cardiovascular diseases; Comparative effectiveness research; Hospitalization; Mortality; Olmesartan

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LOSARTAN; METFORMIN; NITRIC ACID DERIVATIVE; OLMESARTAN; SULFONYLUREA; TELMISARTAN; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG USE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HAZARD RATIO; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INSURANCE; LABORATORY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; YOUNG ADULT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; COMPARATIVE EFFECTIVENESS RESEARCH; HOSPITALIZATION; MORTALITY; OLMESARTAN;

ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL DISEASES; HOSPITALIZATION; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TETRAZOLES; TREATMENT OUTCOME; UNITED STATES;

EID: 84902165464     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02855     Document Type: Article

References (30)

1. Scott LJ, McCormack PL Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008; 68: 1239-1272. (Pubitemid 351822113)
2. Heart.org. ROADMAP Presented; Hypertension Experts React to FDA Review of Olmesartan Safety. 2010. http://www.theheart.org/arti-cle/1090031.do. Accessed December 21, 2013.
3. Imai E, Chan JC, Ito S, Yamasaki T., Kobayashi F, Haneda M, Makino H; ORIENT Study Investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011; 54: 2978-2986.
4. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J., Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbu-minuria in type 2 diabetes. N Engl J Med. 2011; 364: 907-917.
5. US Food and Drug Administration. FDA Drug Safety Communication: Safety Review Update of Benicar (olmesartan) and cardiovascular events. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm251268.htm. Accessed on December 21, 2013.
6. US Food and Drug Administration. Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy). 2013. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm359528.htm. Accessed December 21, 2013.
7. Eurich DT, Simpson S, Senthilselvan A., Asche CV, Sandhu-Minhas JK, McAlister FA Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013; 346:f2267.
8. Riedel AA, Heien H, Wogen J., Plauschinat CA Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metfor-min, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007; 27: 1102-1110. (Pubitemid 47173656)
9. Duh MS, Gosselin A, Luo R., Lohoues H, Lewis BE, Crawley JA Impact of compliance with proton pump inhibitors on NSAID treatment. Am J Manag Care. 2009; 15: 681-688.
10. Segal JB, Dy SM, Millman E.A., Herbert R., Bass EB, Wu A. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy. Clin Ther. 2007; 29: 1784-1794. (Pubitemid 47494552)
11. Rich-Edwards J.W., Corsano KA, Stampfer MJ Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994; 140: 1016-1019. (Pubitemid 24373006)
12. Cowper DC, Kubal JD, Maynard C, Hynes DM A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002; 12: 462-468.
13. Bowker SL, Yasui Y, Veugelers P., Johnson JA Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. 2010; 53: 1631-1637.
14. Lipscombe LL, Gomes T, Lévesque LE, Hux J.E., Juurlink DN, Alter DA Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007; 298: 2634-2643. (Pubitemid 350254955)
15. Penson DF, Stoddard ML, Pasta D.J., Lubeck DP, Flanders SC, Litwin MS The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol. 2001; 54: 350-358. (Pubitemid 32303458)
16. Huberman M, Langholz B. Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol. 1999; 150: 1340-1345.
17. Johns Hopkins. The Johns Hopkins ACG System. 2013. http://www.acg.jhsph. org/. Accessed December 21, 2013.
18. Austin PC, Walraven CV The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011; 49: 940-947.
19. Winkelmayer WC, Setoguchi S, Levin R., Solomon DH Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosi-glitazone vs pioglitazone therapy. Arch Intern Med. 2008; 168: 2368-2375.
20. Swindle JP, Buzinec P, Iorga S.R., Ramaswamy K., Panjabi S. Longterm clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients. Curr Med Res Opin. 2011; 27: 1719-1731.
21. de la Sierra A, Volpe M. Olmesartan-based therapies. J Hypertens. 2013; 31:S13-S17.
22. Zaiken K, Hudd TR, Cheng JW A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications. Ann Pharmacother. 2013; 47: 686-693.
23. Sakata Y, Nochioka K, Miura M., Shiba N, Shimokawa H. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial-rationale and design. J Cardiol. 2013; 62: 31-36.
24. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angioten-sin II subtype 1 receptor blockade in hypertensive patients with micro-inflammation. Circulation. 2004; 110: 1103-1107. (Pubitemid 39319009)
25. Stumpe KO, Agabiti-Rosei E, Zielinski T., Schremmer D, Scholze J, Laeis P., Schwandt P, Ludwig M. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007; 1: 97-106.
26. Hirohata A, Yamamoto K, Miyoshi T., et al Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010; 55: 976-982.
27. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res. 2001; 24: 641-646. (Pubitemid 33133777)
28. Dreifuss SE, Tomizawa Y, Farber N.J., Davison JM, Sohnen AE Spruelike enteropathy associated with olmesartan: an unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013; 2013: 1-3.
29. Rubio-Tapia A., Herman ML, Ludvigsson J.F., Kelly DG, Mangan TF, Wu TT, Murray JA Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012; 87: 732-738.
30. Centers for Disease Control and Prevention (CDC). Deaths and Mortality. 2010. http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-04.pdf. Accessed on December 21, 2013.